The FDA announced it is allowing Florida to import medications in bulk from Canada at far lower prices than those offered in the United States; health insurance companies are revamping their technology to encourage more people to get their medications through the mail; nearly 17,000 patients with COVID-19 may have died after taking hydroxychloroquine during the first pandemic wave.
The FDA announced it is allowing Florida to import medications in bulk from Canada at far lower prices than those offered in the United States, according to the New York Times. Florida estimated that it could save up to $150 million in its first year of the program, which would import drugs for treating HIV/AIDS, hepatitis C, diabetes, and psychiatric conditions. This approval represents a major US policy shift as pharmaceutical companies objected to this practice for decades, and the Pharmaceutical Research and Manufacturers of America (PhRMA), is expected to sue to prevent the plan from going into effect. Despite this, supporters hope this will be a significant step forward in reining in drug prices as other states have applied to the FDA to set up similar programs.
Health insurance companies are revamping their technology to encourage more people to get their medications through the mail, according to the Wall Street Journal. For years, insurance companies have operated their own mail-order prescription businesses, but these can be time-consuming for patients. Consequently, insurers are improving user interfaces to grow existing mail-order businesses. For example, CarelonRx, Elevance Health’s pharmacy benefits manager, rolled out a new digital pharmacy that lets users live chat with pharmacists, compare prescription costs, and arrange mail delivery for maintenance medications and refills. The company noted that it should now take fewer than 5 clicks after opening the app to order a refill and it expects the number of members ordering refills by mail to more than triple in the next few years.
A study published Tuesday reported that nearly 17,000 patients with COVID-19 may have died after taking hydroxychloroquine during the first pandemic wave, according to Politico. The researchers explained that hydroxychloroquine is an antimalarial drug that was prescribed to some hospitalized patients during the first wave of the pandemic despite there being no evidence of its clinical benefits. At the time, then-US President Donald Trump considered it a “miracle cure.” Overall, the researchers estimated that about 16,990 people across 6 countries, including the United States, may have died because of the drug; they noted that the total number may be far higher as the study only analyzed 6 countries.
Despite Record ACA Enrollment, Report Reveals Underinsured Americans are in Crisis
November 21st 2024Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access and affordability to health care.
Read More
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More
Despite Record ACA Enrollment, Report Reveals Underinsured Americans are in Crisis
November 21st 2024Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access and affordability to health care.
Read More
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More
2 Commerce Drive
Cranbury, NJ 08512